IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['myeloid', 'io-108']
today at #aacr23, don't miss an oral presentation at 4:05pm that will detail encouraging ph 1 data for our first-in-class #myeloid #checkpointinhibitor, io-108. join the session to learn why #lilrb2 is a critically important #immunotherapy target. 
Science at Our Core. Patients in Our Hearts.